Akt is frequently abnormally activated in cancers due to aberrant activity of upstream receptors, activating mutations in the catalytic subunit of PI3K (p110 alpha, PIK3CA) or inactivating mutations in the phosphatase and tensin homolog (PTEN) lipid and protein phosphatase. This evidence concerns the gene PTEN and cancer.